Latest Biotech News

Eli Lilly reported results and guidance that outpaced Wall Street expectations, driven by fast-selling GLP-1 medicines, while rival Novo Nordisk issued a downbeat 2026 sales outlook that sent its...

Telehealth provider Hims & Hers started selling a compounded version of Novo Nordisk’s newly approved Wegovy oral formulation, prompting Novo to threaten litigation and regulatory action. Hims...

The administration launched TrumpRx, a consumer-facing portal powered by GoodRx technology to display cash prices for prescription drugs and direct patients to purchase options. Officials pitched...

The FDA re-examined historical trial adjudication data for Tavneos (avacopan) and requested withdrawal; Amgen rejected the agency’s request and said it will continue discussions. The FDA’s action...

Bayer reported Phase 3 results showing asundexian, a factor XIa inhibitor, reduced recurrent ischemic stroke by about 26% without added safety signals, improving the commercial and clinical...

Angitia Biopharmaceuticals closed a $130 million Series D to progress three biologics targeting musculoskeletal diseases into mid‑stage development. The round positions the US‑China company to...

Eikon Therapeutics priced an upsized $381 million initial public offering and will begin trading under ticker EIKN. The company raised the proceeds to advance a clinical-stage oncology portfolio...

Generate:Biomedicines, the Flagship Pioneering–backed AI-driven antibody biotech, filed to go public and is pitching its programmable-biology platform and late-stage asthma asset to investors. The...

Telehealth provider Hims & Hers began selling a compounded pill version of Novo Nordisk’s Wegovy, prompting immediate industry and regulatory blowback. Novo has threatened litigation, calling the...

Bayer reported that its factor XIa inhibitor asundexian reduced ischemic stroke recurrence by 26% in a large phase 3 study, without adding major safety signals. The company released details after...

BARDA opened a $100 million prize competition to accelerate development of broad-spectrum small-molecule antivirals targeting Togaviridae and Flaviviridae families. The multi-stage program aims to...

Illumina is leaning further into healthcare markets after disruptions to NIH funding under the Trump administration rattled basic-research demand for sequencing. Company comments and earnings show...

The FDA revisited years-old data issues around Tavneos (avacopan) and asked Amgen to consider withdrawing the drug; Amgen pushed back and said it is unwilling to pull the product from the market....

Two AI-native ventures signaled momentum: Latent Labs, founded by former DeepMind team members, emerged with a platform to design drug-like biologics for difficult targets; Phylo raised $13.5...

The Joint Action on Personalized Cancer Medicine (JA PCM) launched with €25.3 million from the EU to expand equitable access to personalized prevention, early detection and treatment across 29...

This week’s flurry of IPOs continued as Agomab Therapeutics and SpyGlass Pharma raised a combined $350 million in separate offerings, and Veradermics priced a $256 million IPO for its oral...

Two European and multiple US biotechs priced sizeable offerings this week, reviving investor interest in drug-company IPOs. Belgium-based Agomab and ocular-therapy developer SpyGlass together...

Generate:Biomedicines, the Flagship Pioneering-backed antibody and programmable-biology company, filed for an IPO as it advances phase 3 programs and AI-designed antibody candidates. The filing...

Telehealth provider Hims & Hers announced it will sell a compounded version of Novo Nordisk’s recently approved Wegovy pill, triggering a public clash with Novo and raising immediate legal and...

The White House announced plans to launch TrumpRx, a direct-to-consumer pricing portal built on GoodRx technology to display cash prices for selected medicines and steer patients to purchase...